Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2750396 | 1.00 | MAPK1 (0.35) | MAPK1SMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL631685 | 1.00 | MAPK1 (0.35) | MAPK1SMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL630995 | 0.90 | AURKA (0.37) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| SCHEMBL630994 | 0.90 | AURKA (0.37) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| SCHEMBL634321 | 0.83 | BCL2L1 (0.33) | ALDH1A1AURKAAURKBBRD4KDR | |
| Obatoclax SCHEMBL631676 | 0.82 | RAB9A (0.41) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| Obatoclax SCHEMBL2751250 | 0.82 | RAB9A (0.41) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| Obatoclax SCHEMBL29519876 | 0.82 | RAB9A (0.41) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| Obatoclax SCHEMBL29354696 | 0.82 | RAB9A (0.41) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA | |
| Obatoclax SCHEMBL631677 | 0.82 | RAB9A (0.41) | MAPK1SMN1; SMN2KDM4EALDH1A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | claimed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | claimed |
| EP-1853255-A4 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | GEMIN X PHARMACEUTICALS CANADA (CA) | 2009-07-08 | — | — | EP | disclosed |
| EP-1853255-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | Gemin X Biotechnologies Inc. (CA) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089397-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2006-08-31 | — | — | WO | disclosed |
| EP-1644363-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | Gemin X Biotechnologies Inc. (CA) | 2006-04-12 | — | — | EP | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| WO-2005117908-A2 | TRIHETEROCYCLIC COMPOUNDS COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES, INC. (CA) | 2005-12-15 | — | — | WO | disclosed |
| WO-2004106328-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | MAPK1 3421/4885SMN1; SMN2 4473/4885KDM4E 3253/4885 |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | ZC3HAV1, HCCS, PCNA | MAPK1 2632/4885SMN1; SMN2 4478/4885KDM4E 3444/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | MAPK1 3222/4885SMN1; SMN2 4124/4885KDM4E 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.